Diroximel Fumarate Is Approved for Relapsing Forms of MS, Clinically Isolated Syndrome
October 30th 2019The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.
Trevor Dyson-Hudson, MD: Unseen Consequences of Spinal Cord Injury
October 30th 2019The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation discussed the secondary medical complications of spinal cord injury and how he and colleagues seek to alleviate them.
CBD Shows Long-Term Safety as Add-On Therapy in Lennox-Gastaut Syndrome
October 25th 2019Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.
Vitalis Announces Plans for Low-Flush Formulation Fumarate VTS-72 In Multiple Sclerosis
October 24th 2019VTS-72 is a proprietary combination of fumarate and VTS-Aspirin believed to improve the pharmacokinetics of fumaric acid while improving flush, which is estimated to occur in up to 40% of patients on a fumarate agent.
James Leverenz, MD: Differentiating Lewy Body Dementia
October 24th 2019The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic laid out these challenges that he and his colleagues face in differentiating patients with Lewy body dementia from other dementia pathologies.
FDA Issues Warning Letter for CBD Products to Treat Alzheimer, Parkinson
October 24th 2019The agency sent a joint letter with the FTC to Rooted Apothecary LLC for claiming its CBD products can medically treat a number of conditions including Alzheimer disease and Parkinson disease. Since 2017, the FDA has issued more than 10 such letters.
Anup Patel, MD: Transmitting Epilepsy Information Correctly
October 23rd 2019The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.
New Parkinson Disease Biomarker Provides Opportunity for Drug Development
October 23rd 2019SynapCell and Motac Neuroscience recently announced a novel biomarker, BetaPark [evo], for Parkinson disease progression. The chief innovation officer at SynapCell provided insight into the clinical implications of this discovery.
Neuromodulation Device Has Significant Effect on Essential Tremor Treatment
October 23rd 2019The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton and principal investigator of the PROSPECT study, offered insight into the clinical impact and advantages of the Cala Trio neuromodulation device.
Trevor Dyson-Hudson, MD: Spinal Cord Injury Model Systems
October 23rd 2019The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury as someone who experienced it.
Aducanumab Heads to the FDA After Biogen Analysis Proves Positive in Early Alzheimer Disease
October 22nd 2019After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease.
Essential Tremor Symptoms, Severity Improved With Cala Trio Neuromodulation Device
October 22nd 2019The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.